5/1
07:15 am
cgem
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.
4/29
07:00 am
cgem
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Medium
Report
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
4/24
04:34 pm
cgem
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? [Yahoo! Finance]
Medium
Report
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? [Yahoo! Finance]
4/24
10:09 am
cgem
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Medium
Report
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
4/22
01:09 pm
cgem
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Low
Report
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
4/18
08:04 am
cgem
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target raised by analysts at Jonestrading from $22.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target raised by analysts at Jonestrading from $22.00 to $26.00. They now have a "buy" rating on the stock.
4/16
01:18 pm
cgem
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target lowered by analysts at HC Wainwright from $34.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target lowered by analysts at HC Wainwright from $34.00 to $29.00. They now have a "buy" rating on the stock.
4/16
07:19 am
cgem
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases [Yahoo! Finance]
High
Report
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases [Yahoo! Finance]
4/16
07:19 am
cgem
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement [Yahoo! Finance]
High
Report
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement [Yahoo! Finance]
4/16
07:00 am
cgem
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
High
Report
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
4/16
06:59 am
cgem
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
High
Report
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
4/15
08:18 am
cgem
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
4/15
08:13 am
cgem
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer [Yahoo! Finance]
Low
Report
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer [Yahoo! Finance]
3/18
03:05 pm
cgem
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Low
Report
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
3/15
08:08 am
cgem
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation [Yahoo! Finance]
3/14
07:18 am
cgem
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/14
07:00 am
cgem
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
3/1
07:20 am
cgem
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
Medium
Report
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
3/1
07:00 am
cgem
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Low
Report
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
2/27
08:00 am
cgem
Cullinan Oncology to Participate in Upcoming Investor Conferences
Low
Report
Cullinan Oncology to Participate in Upcoming Investor Conferences
2/15
07:17 am
cgem
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Wedbush. They set an "outperform" rating and a $30.00 price target on the stock.
Low
Report
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Wedbush. They set an "outperform" rating and a $30.00 price target on the stock.